Solid Tumor Clinical Trial
Official title:
An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) In Pediatric and Young Adult Patients With Previously Treated Solid Tumors
Verified date | February 2020 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This early phase, multicenter, open-label, single-arm study evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of atezolizumab in pediatric and young adult participants with solid tumors for which prior treatment was proven to be ineffective.
Status | Terminated |
Enrollment | 87 |
Est. completion date | June 6, 2019 |
Est. primary completion date | June 6, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 30 Years |
Eligibility |
Inclusion Criteria: - Pediatric solid tumor (including Hodgkin's and Non-Hodgkin's lymphoma), for which prior treatment had proven to be ineffective (that is, relapsed or refractory) or intolerable - Disease that is measurable as defined by RECIST v1.1, mINRC, Revised Response Criteria for Malignant Lymphoma, RANO criteria (as appropriate) or evaluable by nuclear medicine techniques, immunocytochemistry techniques, tumor markers, or other reliable measures - Archival tumor tissue block or 15 freshly cut, unstained, serial slides available for submission, or willingness to undergo a core or excisional biopsy prior to enrollment (fine-needle aspiration, brush biopsy, and lavage samples are not acceptable). Participants with fewer than 15 slides available may be eligible for study entry following discussion with Medical Monitor - Lansky Performance Status (participants less than [<] 16 years old) or Karnofsky Performance Status (participants greater than or equal to [>=] 16 years old) >=50 - Life expectancy >=3 months, in the investigator's judgment - Adequate hematologic and end organ function, confirmed by laboratory results obtained within 28 days prior to initiation of study drug Exclusion Criteria: - Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases, except ATRT - Treatment with high-dose chemotherapy and hematopoietic stem-cell rescue within 3 months prior to initiation of study drug - Prior allogeneic hematopoietic stem-cell transplantation or prior solid-organ transplantation - Treatment with chemotherapy (other than high-dose chemotherapy as described above) or differentiation therapy (such as retinoic acid) or immunotherapy (such as anti-GD2 antibody treatment) within 3 weeks prior to initiation of study drug or, if treatment included nitrosoureas, within 6 weeks prior to initiation of study drug - Treatment with thoracic or mediastinal radiotherapy within 3 weeks prior to initiation of study drug - Treatment with hormonal therapy (except hormone replacement therapy or oral contraceptives) or biologic therapy within 4 weeks or 5 half-lives, whichever is shorter, prior to initiation of study drug. This requirement may be waived at the investigator's request if the participant has recovered from therapeutic toxicity to the degree specified in the protocol, with approval of the Medical Monitor - Treatment with a long-acting hematopoietic growth factor within 2 weeks prior to initiation of study drug or a short-acting hematopoietic growth factor within 1 week prior to initiation of study drug - Treatment with investigational therapy (with the exception of cancer therapies as described above) within 4 weeks prior to initiation of study drug - Treatment with a live vaccine or a live, attenuated vaccine (e.g., nasal spray of live attenuated influenza vaccine or FluMistĀ®) within 4 weeks prior to initiation of study drug or anticipation that such treatment will be required during the study or within 5 months after the final dose of study drug - Treatment with herbal cancer therapy within 1 week prior to initiation of study drug - Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4), anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibodies - Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin 2 [IL-2]) within 6 weeks or five drug elimination half-lives prior to Day 1 of Cycle 1, whichever is longer - Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) at the time of initiation of study drug, or anticipated requirement for systemic immunosuppressive medications during the study - Current treatment with therapeutic anticoagulants - Any non-hematologic toxicity (excluding alopecia) from prior treatment that has not resolved to Grade less than or equal to (<=) 1 (per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) at screening - Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation |
Country | Name | City | State |
---|---|---|---|
Canada | Alberta Children'S Hospital | Calgary | Alberta |
Denmark | Rigshospitalet; BØRNEUNGEKLINIKKEN, Ambulatoriet for kræft- og Blodsygdomme hos børn og unge | København Ø | |
France | Centre Léon Bérard, Institut d'Hémato-Oncologie Pédiatrique | Lyon | |
France | Institut Curie, Oncologie Pédiatrique | Paris | |
France | Institut Gustave Roussy; Service Pediatrique | Villejuif | |
Germany | Klinik Johann Wolfgang von Goethe Uni | Frankfurt | |
Israel | Schneider Children's Medical Center | Petach-Tikva | |
Italy | IRCCS Istituto Giannina Gaslini; Unità Operativa Oncologica Pediatrica | Genova | Liguria |
Italy | Fondazione IRCCS Istituto Nazionale dei Tumori; Struttura Complessa di Pediatria Oncologica | Milano | Lombardia |
Italy | Azienda Ospedaliera di Padova; Clinica di Onco-ematologia pediatrica | Padova | Veneto |
Italy | Ospedale Pediatrico Bambino Gesù - IRCCS; Dipartimento di Onco-Ematologia Pediatrica | Roma | Lazio |
Italy | Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino | Torino | Piemonte |
Netherlands | Erasmus MC / location Sophia Kinderziekenhuis | Rotterdam | |
Spain | Hospital Universitari Vall d'Hebron | Barcelona | |
Spain | Hospital Sant Joan De Deu | Esplugues De Llobregas | Barcelona |
Spain | Hospital Infantil Universitario Nino Jesus | Madrid | |
Spain | Hospital Universitari i Politecnic La Fe de Valencia | Valencia | |
Switzerland | Universitäts-Kinderspital; Abteilung für Onkologie | Zürich | |
United Kingdom | Birmingham Children's Hospital | Birmingham | |
United Kingdom | Bristol Royal Hospital For Children | Bristol | |
United Kingdom | Leeds General Infirmary; Paediatric Oncology & Haematology | Leeds | |
United Kingdom | The Royal Victoria Infirmary; Paediatric and Adolescent Oncology Unit | Newcastle Upon Tyne | |
United Kingdom | Royal Marsden Hospital; Pediatric Unit | Surrey | |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Penn State Milton S. Hershey Medical Center | Hershey | Pennsylvania |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Arkansas Children'S Hospital | Little Rock | Arkansas |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Stanford University/Lucile Packard Children's Hospital | Palo Alto | California |
United States | University of Texas Health Science Center at San Antonio | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
United States, Canada, Denmark, France, Germany, Israel, Italy, Netherlands, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Participants With Solid Tumors | Note: In Cohort 5, the response was observed in a rhabdoid tumor. Participant was erroneously enrolled in the Non-rhabdomyosarcoma soft tissue sarcoma cohort. | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | |
Primary | Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) in Participants With Neuroblastoma | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Primary | Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Primary | Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Response Assessment in Neuro-Oncology (RANO) Criteria in Participants With Atypical Teratoid Rhabdoid Tumor (ATRT) | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Primary | Percentage of Participants With Clinical Benefit as Determined by the Investigator According to RECIST v1.1 Criteria in Participants With Osteosarcoma | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Primary | Progression-Free Survival (PFS) as Determined by the Investigator Using RECIST v1.1 in Participants With Solid Tumors | Baseline until first documented occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Primary | PFS as Determined by the Investigator Using mINRC in Participants With Neuroblastoma | Baseline until first documented occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Primary | PFS as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | Baseline until first documented occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Primary | PFS as Determined by the Investigator Using RANO Criteria in Participants With ATRT | Baseline until first documented occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Primary | Percentage of Participants Adverse Events, Serious Adverse Events and Adverse Events of Special Interest | From baseline up to approximately 42 months | ||
Primary | Maximum Serum Concentration (Cmax) of Atezolizumab | Predose (PRD; 0 hours [hr]), 0.5 hr post-infusion (P-I; infusion duration=30-60 minutes) on Day (D) 1 of Cycle (Cy) 1 and 4 (1 Cy=21 days) | ||
Primary | Minimum Serum Concentration (Cmin) of Atezolizumab | PRD (0 hr) on D1 of Cy2,3,4,8, 12, 16 (1 Cy=21 days) and every 8 cycles thereafter; at any time during visit at study drug discontinuation visit, at least 90 days (maximum 150 days) after the last dose of study drug (up to approximately 42 months) | ||
Primary | Atezolizumab Serum Concentration at Washout | At least 90 days (maximum 150 days) after last dose of study drug (up to approximately 42 months) | ||
Primary | Area Under the Concentration-Time Curve (AUC) of Atezolizumab | PRD (0 hr), 0.5 hr P-I (infusion duration=30-60 minutes) on D1 of Cy1; at any time during visit on Cy1D8 (1 Cy=21 days) | ||
Primary | Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab | PRD (0 hr) on D1 of Cy1,2,3,4,8,12,16 (1 Cy=21 days) & every 8 cycles thereafter; at any time during visit on Cy1D8, study drug discontinuation, at least 90 days (maximum 150 days) after last dose of study drug (up to approximately 42 months) | ||
Secondary | Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 Criteria in Participants With Solid Tumors | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Secondary | DOR as Determined by the Investigator Using mINRC in Participants With Neuroblastoma | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Secondary | DOR as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Secondary | DOR as Determined by the Investigator Using RANO Criteria in Participants With ATRT | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Secondary | Overall Survival (OS) | Baseline until death (up to approximately 42 months) | ||
Secondary | Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Immune-Modified RECIST v1.1 for Participants With Other Solid Tumors | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Secondary | Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Immune-Related Response Criteria (irRC) for Participants With Neuroblastoma | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Secondary | Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using irRC for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Secondary | PFS as Determined by the Investigator Using Immune-Modified RECIST v1.1 for Participants With Other Solid Tumors | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Secondary | PFS as Determined by the Investigator Using irRC for Participants With Neuroblastoma | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Secondary | PFS as Determined by the Investigator Using irRC for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Secondary | DOR as Determined by the Investigator Using Immune-Modified RECIST v1.1 for Participants With Other Solid Tumors | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Secondary | DOR as Determined by the Investigator Using irRC for Participants With Neuroblastoma | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Secondary | DOR as Determined by the Investigator Using irRC for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months) | ||
Secondary | Optimal Dose of Atezolizumab in Pediatric Adult Participants | Atezolizumab was administered on Day 1 only for a cycle duration of 3 weeks. | From baseline up to approximately 42 months | |
Secondary | Optimal Dose of Atezolizumab in Young Adult Participants | Atezolizumab was administered on Day 1 only for a cycle duration of 3 weeks. | From baseline up to approximately 42 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05580991 -
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Recruiting |
NCT05159388 -
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06014502 -
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04107311 -
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
|
||
Active, not recruiting |
NCT04078152 -
Durvalumab Long-Term Safety and Efficacy Study
|
Phase 4 | |
Completed |
NCT02250157 -
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03943004 -
Trial of DFP-14927 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Recruiting |
NCT05798546 -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
|
Phase 1 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT00479128 -
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04143789 -
Evaluation of AP-002 in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 |